ArticleAnalytical and bioanalytical chemistry2026
Dextran sulfate restores endotoxin detectability in human serum.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Accurate quantification of endotoxins in human serum is essential for both clinical diagnostics and biomedical research but is frequently compromised by low endotoxin recovery (LER) in Limulus amebocyte lysate (LAL) assays. Here, we systematically evaluated natural and synthetic polyanions as additives to neutralize HDPs and restore LAL-detectable endotoxin activity in human serum. Dextran sulfate, polyacrylic acid, fondaparinux, enoxaparin, and chondroitin sulfate were screened using complementary bacterial growth assays and kinetic chromogenic LAL measurements. Among all tested compounds, dextran sulfate (DS40) showed the highest efficacy in neutralizing serum-derived HDPs. At an optimized concentration of 0.06 mg/mL, DS40 consistently restored endotoxin recovery within pharmacopeial acceptance criteria (50-200%) for purified and naturally occurring endotoxins derived from Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Performance was comparable to unfractionated heparin, a previously established HDP-neutralizing additive. Importantly, DS40 did not interfere with assay linearity or sensitivity and fully complied with European Pharmacopoeia requirements for the absence of interfering factors. Compared to heparin, DS40 offers superior batch-to-batch consistency, lower cost, improved sustainability, and eliminates the use of animal-derived components. These findings establish DS40 as a robust, chemically defined additive for overcoming LER and enabling reliable endotoxin quantification in human serum, thereby improving the analytical performance of LAL-based assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.